Barclays PLC Arcutis Biotherapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 253,392 shares of ARQT stock, worth $3.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

253,392

Previous 253,392 -0.0%

Holding current value

$3.58 Million

Previous $2.36 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$8.32 - $11.0 $1.26 Million - $1.66 Million	151,279 Added 148.15%	253,392 $2.36 Million
Q2 2024 Aug 14, 2024	BUY	$7.24 - $12.53 $26,121 - $45,208	3,608 Added 3.66%	102,113 $949,000
Q1 2024 May 15, 2024	SELL	$3.25 - $11.77 $33,003 - $119,524	-10,155 Reduced 9.35%	98,505 $976,000
Q4 2023 Feb 15, 2024	SELL	$1.84 - $4.82 $181,087 - $474,369	-98,417 Reduced 47.53%	108,660 $351,000
Q3 2023 Nov 07, 2023	SELL	$5.31 - $10.98 $139,870 - $289,224	-26,341 Reduced 11.28%	207,077 $1.1 Million
Q2 2023 Aug 03, 2023	SELL	$7.51 - $15.0 $8.24 Million - $16.4 Million	-1,096,647 Reduced 82.45%	233,418 $2.22 Million
Q1 2023 May 04, 2023	BUY	$10.23 - $17.14 $1.53 Million - $2.57 Million	149,681 Added 12.68%	1,330,065 $14.6 Million
Q4 2022 Feb 13, 2023	BUY	$13.96 - $20.4 $14.5 Million - $21.2 Million	1,039,547 Added 738.12%	1,180,384 $17.5 Million
Q3 2022 Nov 03, 2022	BUY	$17.85 - $26.95 $1.89 Million - $2.86 Million	106,001 Added 304.29%	140,837 $2.69 Million
Q2 2022 Aug 12, 2022	SELL	$16.33 - $22.2 $50,655 - $68,864	-3,102 Reduced 8.18%	34,836 $742,000
Q1 2022 May 16, 2022	BUY	$14.38 - $22.79 $545,548 - $864,607	37,938 New	37,938 $730,000

Others Institutions Holding ARQT

# of Institutions

197

Shares Held

129M

Call Options Held

738K

Put Options Held

82K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $849M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account